JP6615755B2 - インフルエンザウイルスの複製の阻害剤 - Google Patents

インフルエンザウイルスの複製の阻害剤 Download PDF

Info

Publication number
JP6615755B2
JP6615755B2 JP2016529944A JP2016529944A JP6615755B2 JP 6615755 B2 JP6615755 B2 JP 6615755B2 JP 2016529944 A JP2016529944 A JP 2016529944A JP 2016529944 A JP2016529944 A JP 2016529944A JP 6615755 B2 JP6615755 B2 JP 6615755B2
Authority
JP
Japan
Prior art keywords
compound
composition
administered
influenza
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016529944A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016537346A5 (enExample
JP2016537346A (ja
Inventor
クワミ ダブリュー． ヌティ−アッダイ，
マイケル ウォルドー，
サイモン アダム オニール，
アルステン， ジョン グレッグ バン
ダイニウス マシケナス，
プラビーン ムドゥヌリ，
イ シ，
マーク ウィレム レデボア，
バルダス ジャーコースカス，
アレス メデク，
スティーブン ジョーンズ，
ランダル バーン，
モハメド アスマル，
サラ マリー ロバートソン，
ワンジュン ツァイ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2016537346A publication Critical patent/JP2016537346A/ja
Publication of JP2016537346A5 publication Critical patent/JP2016537346A5/ja
Application granted granted Critical
Publication of JP6615755B2 publication Critical patent/JP6615755B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016529944A 2013-11-13 2014-11-12 インフルエンザウイルスの複製の阻害剤 Expired - Fee Related JP6615755B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361903572P 2013-11-13 2013-11-13
US61/903,572 2013-11-13
PCT/US2014/065114 WO2015073476A1 (en) 2013-11-13 2014-11-12 Inhibitors of influenza viruses replication

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019000201A Division JP2019048898A (ja) 2013-11-13 2019-01-04 インフルエンザウイルスの複製の阻害剤

Publications (3)

Publication Number Publication Date
JP2016537346A JP2016537346A (ja) 2016-12-01
JP2016537346A5 JP2016537346A5 (enExample) 2017-12-21
JP6615755B2 true JP6615755B2 (ja) 2019-12-04

Family

ID=51952043

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016529944A Expired - Fee Related JP6615755B2 (ja) 2013-11-13 2014-11-12 インフルエンザウイルスの複製の阻害剤
JP2019000201A Pending JP2019048898A (ja) 2013-11-13 2019-01-04 インフルエンザウイルスの複製の阻害剤
JP2020098516A Withdrawn JP2020128441A (ja) 2013-11-13 2020-06-05 インフルエンザウイルスの複製の阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019000201A Pending JP2019048898A (ja) 2013-11-13 2019-01-04 インフルエンザウイルスの複製の阻害剤
JP2020098516A Withdrawn JP2020128441A (ja) 2013-11-13 2020-06-05 インフルエンザウイルスの複製の阻害剤

Country Status (27)

Country Link
US (1) US9771361B2 (enExample)
EP (2) EP3578554A1 (enExample)
JP (3) JP6615755B2 (enExample)
KR (1) KR102353413B1 (enExample)
CN (2) CN105849100B (enExample)
AU (1) AU2014348840B2 (enExample)
CA (1) CA2930103A1 (enExample)
CL (1) CL2016001110A1 (enExample)
CY (1) CY1121919T1 (enExample)
DK (1) DK3068776T3 (enExample)
ES (1) ES2741444T3 (enExample)
HR (1) HRP20191525T1 (enExample)
HU (1) HUE044667T2 (enExample)
IL (1) IL245585B (enExample)
LT (1) LT3068776T (enExample)
ME (1) ME03460B (enExample)
MX (1) MX382171B (enExample)
NZ (1) NZ719729A (enExample)
PL (1) PL3068776T3 (enExample)
PT (1) PT3068776T (enExample)
RS (1) RS59144B1 (enExample)
RU (1) RU2700415C1 (enExample)
SG (1) SG10201804026WA (enExample)
SI (1) SI3068776T1 (enExample)
SM (1) SMT201900450T1 (enExample)
UA (1) UA121376C2 (enExample)
WO (1) WO2015073476A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020128441A (ja) * 2013-11-13 2020-08-27 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104151312B (zh) 2009-06-17 2016-06-15 沃泰克斯药物股份有限公司 流感病毒复制抑制剂
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
RS57541B1 (sr) 2013-11-13 2018-10-31 Vertex Pharma Postupci za pripremu inhibitora replikacije virusa gripa
AU2015298876B2 (en) 2014-08-08 2020-02-13 Janssen Sciences Ireland Uc Indoles for use in influenza virus infection
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
CN106854205B (zh) * 2015-12-09 2019-07-09 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
WO2018137670A1 (zh) * 2017-01-24 2018-08-02 苏州科睿思制药有限公司 一种病毒蛋白抑制剂药物vx-787的晶型及其制备方法和用途
CN110603041A (zh) * 2017-04-12 2019-12-20 沃泰克斯药物股份有限公司 用于治疗流感病毒感染的组合治疗
WO2019193428A1 (en) 2018-04-06 2019-10-10 Janssen Pharmaceuticals, Inc. Isothermal reactive crystallisation process for the preparation of a crystalline form of pimodivir hydrochloride hemihydrate
TW202031293A (zh) * 2018-11-13 2020-09-01 美商共結晶製藥公司 流感治療劑之調配物
WO2020212399A1 (en) 2019-04-15 2020-10-22 Janssen Pharmaceutica Nv Method for preparing an alkyl trans-3-aminobicyclo[2.2.2]octane-2-carboxylic acid ester compound
CN112079785B (zh) * 2019-06-13 2023-08-04 中国科学院上海药物研究所 一种新型抗流感病毒奥司他韦衍生物、其制备方法及用途
WO2021038480A1 (en) * 2019-08-27 2021-03-04 Janssen Pharmaceuticals, Inc. Combinations for treating influenza virus
US11462418B2 (en) 2020-01-17 2022-10-04 Taiwan Semiconductor Manufacturing Co., Ltd. Integrated circuit package and method
IL294989A (en) * 2020-01-24 2022-09-01 Regeneron Pharma Conjugated protein-antiviral compounds
CN112578034B (zh) * 2020-11-04 2022-02-11 广东众生睿创生物科技有限公司 一种手性胺小分子及其盐的质量控制方法

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4349552A (en) 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
NZ221717A (en) 1986-09-10 1990-08-28 Sandoz Ltd Azaindole and indolizine derivatives and pharmaceutical compositions
WO1990007926A1 (en) 1989-01-20 1990-07-26 Pfizer Inc. 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
FR2687402B1 (fr) 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
DE4304455A1 (de) 1993-02-15 1994-08-18 Bayer Ag Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
IL129871A (en) 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
WO1995033748A1 (en) 1994-06-09 1995-12-14 Smithkline Beecham Corporation Endothelin receptor antagonists
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
WO2000040554A1 (en) 1999-01-07 2000-07-13 American Home Products Corporation Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
US6313126B1 (en) 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
WO2000040581A1 (en) 1999-01-07 2000-07-13 American Home Products Corporation 3,4-dihydro-2h-benzo[1,4]oxazine derivatives
US6265403B1 (en) 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
AR028475A1 (es) 1999-04-22 2003-05-14 Wyeth Corp Derivados de azaindol y uso de los mismos para la manufactura de un medicamento para el tratamiento de la depresion.
US20030153560A1 (en) 1999-04-23 2003-08-14 Salituro Francesco G. Inhibitors of c-Jun N-terminal kinases (JNK)
JP2003503456A (ja) 1999-07-02 2003-01-28 スチュアート エイ． リプトン 神経傷害またはアポトーシスを軽減する方法
GB9919843D0 (en) 1999-08-20 1999-10-27 Smithkline Beecham Plc Novel compounds
DE19948417A1 (de) 1999-10-07 2001-04-19 Morphochem Ag Imidazol-Derivate und ihre Verwendung als Arzneimittel
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
CN1429222A (zh) 2000-02-17 2003-07-09 安姆根有限公司 激酶抑制剂
US7041277B2 (en) 2000-03-10 2006-05-09 Cadbury Adams Usa Llc Chewing gum and confectionery compositions with encapsulated stain removing agent compositions, and methods of making and using the same
CA2308994A1 (en) 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
NZ524192A (en) 2000-08-14 2005-02-25 Ortho Mcneil Pharm Inc Substituted pyrazoles
RU2290179C2 (ru) 2000-09-06 2006-12-27 Орто-Макнейл Фармасьютикал, Инк. Способ лечения аллергий с использованием замещенных пиразолов
WO2002020013A2 (en) 2000-09-06 2002-03-14 Ortho Mcneil Pharmaceutical, Inc. A method for treating allergies using substituted pyrazoles
ES2290187T3 (es) 2000-12-22 2008-02-16 Wyeth Compuestos de heterociclilindazol y azaindazol como ligandos de 5-hidroxitriptamina-6.
US20030165873A1 (en) 2001-03-02 2003-09-04 Come Jon H. Three hybrid assay system
EP1392697B1 (en) 2001-03-14 2004-11-03 Wyeth Antidepressant azaheterocyclymethyl derivatives of 2,3-dihydro-1,4-dioxino 2,3-f]quinoline
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
WO2002085896A1 (en) 2001-04-24 2002-10-31 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan
US6656950B2 (en) 2001-04-25 2003-12-02 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine
WO2002088129A1 (en) 2001-04-26 2002-11-07 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinazoline
DE60206048T2 (de) 2001-04-26 2006-07-13 Wyeth Antidepressive (sssri) azaheterocyclylmethylderivate von 7,8-dihydro-3h-6,9-dioxa-1,3-diazacyclopenta [a] naphthalin
US6593350B2 (en) 2001-04-26 2003-07-15 Wyeth Antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole
US6552049B2 (en) 2001-04-26 2003-04-22 Wyeth Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans
BR0209342A (pt) 2001-04-26 2004-06-15 Wyeth Corp Antidepressivos de azaheterociclilmetila derivados de 2,3 dihidro-1,4-dioxino[2,3-f]quinoxalina; método de tratamento usando tais compostos; processo para prepará-los
MXPA03009829A (es) 2001-04-30 2005-03-07 Wyeth Corp Azaheterociclilmetil derivados de 7,8-dihidro-1,6,9-trioxa-3-azaciclopenta[a]naftaleno como agentes antidepresivos.
US6555560B2 (en) 2001-04-30 2003-04-29 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
GB0111186D0 (en) 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
AU2002309769B2 (en) 2001-05-17 2008-04-17 Wyeth Processes for the synthesis of derivatives of 2,3-dihydro-1,4-dioxino-[2,3-f] quinoline
MXPA03011652A (es) 2001-06-15 2004-05-31 Vertex Pharma 5-(2-aminopirimidin-4-il) benzioxazoles como inhibidores de proteinas cinasa.
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
AR035083A1 (es) 2001-07-25 2004-04-14 Wyeth Corp Derivados azaheterociclilmetilicos de 7,8-dihidro-6h-5-oxa-1-aza-fenantreno, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de un medicamento antidepresivo e intermediarios
WO2003015798A1 (fr) 2001-08-14 2003-02-27 Toyama Chemical Co., Ltd. Nouvelle methode virocide/inhibitrice de la proliferation virale et nouvel analogue de pyradine nucleotide/pyradine nucleoside
US20040236110A1 (en) 2001-09-26 2004-11-25 Ladouceur Gaetan H Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
US6667322B2 (en) 2001-10-05 2003-12-23 Wyeth Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole
US7361671B2 (en) 2001-11-15 2008-04-22 The Institute For Pharmaceutical Discovery, Inc. Substituted heteroarylalkanoic acids
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
AU2003216660A1 (en) 2002-04-26 2003-11-10 Pfizer Products Inc. N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
EP1506189A1 (en) 2002-04-26 2005-02-16 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
TW200406385A (en) 2002-05-31 2004-05-01 Eisai Co Ltd Pyrazole compound and pharmaceutical composition containing the same
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
CA2494100C (en) 2002-08-02 2011-10-11 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of gsk-3
WO2004014912A1 (en) 2002-08-08 2004-02-19 Ribapharm Inc. Improved synthesis for hydroxyalkylated heterocyclic bases
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
WO2004037814A1 (en) 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
BR0318145A (pt) 2003-02-26 2006-02-21 Boehringer Ingelheim Pharma dihidropteridinonas, processos para a sua preparação e sua aplicação como medicamento
EP1599475A2 (en) 2003-03-06 2005-11-30 Eisai Co., Ltd. Jnk inhibitors
US7169801B2 (en) 2003-03-17 2007-01-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
WO2005000813A1 (en) 2003-05-30 2005-01-06 Imclone Systems Incorporated Heteroarylamino-phenylketone derivatives and their use as kinase inhibitors
WO2004106298A1 (en) 2003-05-30 2004-12-09 Janssen Pharmaceutica N.V. Indole derivatives with an improved antipsychotic activity
WO2005012304A2 (en) 2003-07-16 2005-02-10 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
EP1675830A4 (en) 2003-09-30 2008-08-20 Scios Inc HETEROCYCLIC AMIDES AND SULFONAMIDES
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
US20070066641A1 (en) 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
WO2005062795A2 (en) 2003-12-19 2005-07-14 Plexxikon, Inc. Compounds and methods for development of ret modulators
GB0405055D0 (en) 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
EP1730146B1 (en) 2004-03-30 2011-05-04 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of jak and other protein kinases
RU2006138621A (ru) 2004-04-02 2008-05-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Азаиндолы, полезные в качестве ингибиторов rock и других протеинкиназ
ITMI20040874A1 (it) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
KR100476851B1 (ko) 2004-05-18 2005-03-17 (주)성신엔지니어링 중력식 섬유여과기
WO2006009755A2 (en) 2004-06-17 2006-01-26 Plexxikon, Inc. Azaindoles modulating c-kit activity and uses therefor
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US20060122213A1 (en) 2004-06-30 2006-06-08 Francoise Pierard Azaindoles useful as inhibitors of protein kinases
EP1781654A1 (en) 2004-07-27 2007-05-09 SGX Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AU2005294575B2 (en) 2004-10-04 2011-11-24 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
KR20070090172A (ko) 2004-11-04 2007-09-05 버텍스 파마슈티칼스 인코포레이티드 단백질 키나아제의 억제제로서 유용한피라졸로[1,5-ａ]피리미딘
AU2005309566A1 (en) 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or Rho kinase
JP4954086B2 (ja) 2004-12-08 2012-06-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー １ｈ−ピロロ［２，３−ｂ］ピリジン
MX2007007330A (es) 2004-12-16 2007-10-04 Vertex Pharma Piridonas de utilidad como inhibidores de quinasas .
US20060161001A1 (en) 2004-12-20 2006-07-20 Amgen Inc. Substituted heterocyclic compounds and methods of use
US8633205B2 (en) 2005-02-03 2014-01-21 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein kinases
CA2608333A1 (en) 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
EP2354139A1 (en) 2005-05-20 2011-08-10 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
NZ565255A (en) 2005-06-22 2010-04-30 Plexxikon Inc Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
EP1749523A1 (en) 2005-07-29 2007-02-07 Neuropharma, S.A. GSK-3 inhibitors
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
CA2623032A1 (en) 2005-09-30 2007-04-12 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
CN101365700A (zh) 2005-11-15 2009-02-11 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氮杂吲唑
US20130096302A1 (en) 2005-11-22 2013-04-18 Hayley Binch Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
AU2007207533B8 (en) 2006-01-17 2012-06-28 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of Janus kinases
CA2652648C (en) 2006-02-14 2016-10-25 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
EP2004645A2 (en) 2006-02-14 2008-12-24 Vertex Pharmaceuticals, Inc. Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
DE102006012617A1 (de) 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
EP2001884A1 (en) 2006-04-05 2008-12-17 Vertex Pharmaceuticals, Inc. Deazapurines useful as inhibitors of janus kinases
US8252792B2 (en) 2006-04-26 2012-08-28 F. Hoffman-La Roche Ag Pyrimidine derivatives as PI3K inhibitors
WO2007129195A2 (en) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
US20090017444A1 (en) 2006-06-09 2009-01-15 Wisconsin Alumni Research Foundation Screening method for modulators of viral transcription or replication
EP2038272B8 (en) 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
EP2057140B1 (en) 2006-08-24 2012-08-08 AstraZeneca AB Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
US20130310418A1 (en) 2006-11-15 2013-11-21 Vertex Pharmaceuticals Incorporated Azaindazoles useful as inhibitors of kinases
ES2359467T3 (es) 2006-12-14 2011-05-23 Vertex Pharmceuticals Incorporated Compuestos útiles como inhibidores de proteína quinasas.
EP2124951B1 (en) 2006-12-21 2014-05-21 Vertex Pharmaceuticals Inc. 5-cyan0-4- (pyrrolo[2, 3b]pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
TW200840581A (en) 2007-02-28 2008-10-16 Astrazeneca Ab Novel pyrimidine derivatives
EP2137183B1 (en) 2007-03-09 2011-09-28 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
NZ579483A (en) 2007-03-09 2012-07-27 Vertex Pharma Aminopyridines useful as inhibitors of protein kinases
ES2435997T3 (es) 2007-03-09 2013-12-26 Vertex Pharmaceuticals, Inc. Aminopirimidinas útiles como inhibidores de las proteínas cinasas
WO2008113711A1 (en) 2007-03-22 2008-09-25 F. Hoffmann-La Roche Ag Substituted pyrimidodiazepines useful as plk1 inhibitors
RU2339637C1 (ru) 2007-04-05 2008-11-27 Андрей Александрович Иващенко Блокаторы гистаминного рецептора для фармацевтических композиций, обладающих противоаллергическим и аутоиммунным действием
UA98324C2 (ru) 2007-04-05 2012-05-10 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1H-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
CN101790532B (zh) 2007-07-31 2013-11-20 沃泰克斯药物股份有限公司 5-氟-1H-吡唑并[3，4-b]吡啶-3-胺及其衍生物的制备方法
NZ583061A (en) 2007-08-15 2012-06-29 Vertex Pharma 4-(9-(3,3-difluorocyclopentyl)-5,7,7-trimethyl-6-oxo-6,7,8,9-tetrahydro-5h-pyrimido[4,5-b[1,4]diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases
WO2009040556A1 (en) 2007-09-28 2009-04-02 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
CN101970465B (zh) 2007-10-09 2016-03-16 欧洲分子生物学实验室(Embl) 能够结合rna帽的流感病毒pb2蛋白可溶性片段
JP5444239B2 (ja) 2007-11-02 2014-03-19 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼＣ−θとしての［１Ｈ−ピラゾロ［３，４−Ｂ］ピリジン−４−イル］−フェニレンまたは−ピリジン−２−イル誘導体
EP2262498A2 (en) 2008-03-10 2010-12-22 Vertex Pharmceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
EP2297200A1 (en) 2008-04-09 2011-03-23 Technion Research & Development Foundation Ltd. Anti influenza antibodies and uses thereof
AU2009271658B2 (en) 2008-06-23 2014-04-10 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
JP5634990B2 (ja) 2008-06-23 2014-12-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ タンパク質キナーゼ阻害剤
WO2010011762A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
MX2011000837A (es) 2008-07-23 2011-04-05 Vertex Pharma Inhibidores de pirazolpiridina cinasa triciclica.
MX2011000839A (es) 2008-07-23 2011-04-05 Vertex Pharma Inhibidores de pirazolpiridina cinasa.
WO2010129668A1 (en) 2009-05-06 2010-11-11 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
CN104151312B (zh) 2009-06-17 2016-06-15 沃泰克斯药物股份有限公司 流感病毒复制抑制剂
WO2011000566A2 (en) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
JP2012533553A (ja) 2009-07-15 2012-12-27 アボット・ラボラトリーズ ピロロピリジン系キナーゼ阻害薬
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
MX2012011655A (es) * 2010-04-07 2012-11-23 Vertex Pharma Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo [d][1-3]dioxol-5-il]ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico.
CA2796388A1 (en) 2010-04-14 2011-10-20 Array Biopharma Inc. 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
EP2563125A4 (en) 2010-04-27 2013-10-02 Merck Sharp & Dohme AZAINDOLE AS JANUSKINASE HEMMER
MX2013006836A (es) * 2010-12-16 2013-09-26 Vertex Pharma Inhibidores de la replicacion de los virus de la influenza.
WO2012083121A1 (en) * 2010-12-16 2012-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
MX2013006840A (es) * 2010-12-16 2014-01-31 Vertex Pharma Inhibidores de la replicacion de los virus de la influenza.
ES2804528T3 (es) 2011-07-05 2021-02-08 Vertex Pharma Procesos y productos intermedios para la producción de azaindoles
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
EP2776036A1 (en) 2011-11-07 2014-09-17 Vertex Pharmaceuticals Incorporated Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor
EP2858984A1 (en) 2012-06-08 2015-04-15 Vertex Pharmaceuticals Inc. Inhibitors of influenza viruses replication
WO2014201332A1 (en) 2013-06-14 2014-12-18 Vertex Pharmaceuticals Incorporated Pharmaceutical combinations useful for treating rheumatoid arthritis
MX2016002176A (es) 2013-08-22 2016-06-23 Vertex Pharma Azaindoles enriquecidos isotopicamente.
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
HUE044667T2 (hu) * 2013-11-13 2019-11-28 Vertex Pharma Influenza vírus replikáció inhibitorok
EP3068434A1 (en) 2013-11-13 2016-09-21 Vertex Pharmaceuticals Inc. Formulations of azaindole compounds
RS57541B1 (sr) 2013-11-13 2018-10-31 Vertex Pharma Postupci za pripremu inhibitora replikacije virusa gripa
MA40773A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus influenza a
MA40772A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus de la grippe a

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020128441A (ja) * 2013-11-13 2020-08-27 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤

Also Published As

Publication number Publication date
RU2700415C1 (ru) 2019-09-17
IL245585A0 (en) 2016-06-30
US20160251353A1 (en) 2016-09-01
EP3068776B1 (en) 2019-05-29
HRP20191525T1 (hr) 2019-11-29
CN105849100B (zh) 2019-07-16
MX382171B (es) 2025-03-13
UA121376C2 (uk) 2020-05-25
KR20160084464A (ko) 2016-07-13
RS59144B1 (sr) 2019-09-30
US9771361B2 (en) 2017-09-26
PT3068776T (pt) 2019-08-26
MX2016006199A (es) 2016-08-08
AU2014348840B2 (en) 2019-06-06
EP3578554A1 (en) 2019-12-11
SMT201900450T1 (it) 2019-09-09
NZ719729A (en) 2022-04-29
JP2016537346A (ja) 2016-12-01
JP2020128441A (ja) 2020-08-27
CY1121919T1 (el) 2020-10-14
SI3068776T1 (sl) 2019-09-30
EP3068776A1 (en) 2016-09-21
CN105849100A (zh) 2016-08-10
CA2930103A1 (en) 2015-05-21
ES2741444T3 (es) 2020-02-11
WO2015073476A1 (en) 2015-05-21
JP2019048898A (ja) 2019-03-28
DK3068776T3 (da) 2019-07-29
IL245585B (en) 2021-07-29
LT3068776T (lt) 2019-08-12
KR102353413B1 (ko) 2022-01-21
PL3068776T3 (pl) 2019-10-31
CL2016001110A1 (es) 2017-10-20
CN110156779A (zh) 2019-08-23
AU2014348840A1 (en) 2016-05-26
HUE044667T2 (hu) 2019-11-28
ME03460B (me) 2020-01-20
SG10201804026WA (en) 2018-06-28

Similar Documents

Publication Publication Date Title
JP6615755B2 (ja) インフルエンザウイルスの複製の阻害剤
JP6618901B2 (ja) インフルエンザウイルスの複製の阻害剤を調製する方法
US20210008072A1 (en) Formulations of azaindole compounds
US10273233B2 (en) Inhibitors of influenza viruses replication
HK40018796A (en) Inhibitors of influenza viruses replication
HK1227859A1 (en) Inhibitors of influenza viruses replication
HK1227859B (en) Inhibitors of influenza viruses replication

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171109

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191010

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191023

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191106

R150 Certificate of patent or registration of utility model

Ref document number: 6615755

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees